Bardoxolone Methyl Polymorphs for Inflammatory Cytokine Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 lack effective therapies to address the severe inflammatory response, acute kidney injury, and organ damage associated with SARS-CoV-2 infection, which often lead to complications such as ARDS, AKI, and multiple organ failure.
Innovation Solution
Bardoxolone methyl and its analogs are administered to patients, exhibiting anti-inflammatory and antiviral properties, reducing pro-inflammatory cytokines, chemokines, and oxidative stress, while protecting kidney function and preventing organ damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for COVID-19, then no specific therapy is available, but severe inflammatory response and organ damage occur
Solution Approach 1:
The patent modifies the chemical structure of bardoxolone by changing physical and chemical parameters (polymorphic forms, crystalline structures) to optimize its anti-inflammatory and antiviral efficacy. Different crystalline forms (Form A, Form B, Form C) are presented with distinct X-ray diffraction patterns, indicating structural parameter changes that enhance therapeutic effectiveness against COVID-19 complications.
Solution Approach 2:
The patent presents multiple analogs and derivatives of bardoxolone methyl, creating molecular copies with modified structures. These analogs include compounds with different substituents (R1-R6 groups) that replicate the core anti-inflammatory activity while potentially improving pharmacokinetic properties and reducing toxicity.
2Object-generated harmful factors
If bardoxolone methyl is administered to reduce inflammation, then pro-inflammatory cytokines decrease, but kidney function must be monitored
Solution Approach 1:
The patent indicates monitoring of kidney function parameters (creatinine clearance, eGFR) as feedback mechanisms to assess the therapeutic effect and safety profile of bardoxolone methyl. This feedback loop allows adjustment of dosing based on individual patient response and kidney function status.
Solution Approach 2:
The patent explores different dosing regimens and pharmacokinetic parameters to optimize the balance between anti-inflammatory efficacy and kidney safety. By adjusting administration parameters (dose, frequency, route), the therapeutic window is narrowed to maximize benefit while minimizing harm to kidney function.
3Productivity
If multiple polymorphic forms of bardoxolone are used, then bioavailability may improve, but formulation complexity increases
Solution Approach 1:
The patent systematically evaluates different crystalline forms (Form A with peaks at 8.8, 12.9, 13.4, 14.2, 17.4°; Form B with peaks at 6.2, 12.4, 15.4, 18.6, 24.9°; Form C with peaks at 3.6, 7.1, 10.8, 12.4, 16.5°) to determine which polymorphic form provides optimal bioavailability and pharmacokinetic profile, selecting the best parameter set rather than using all possible forms.
Data Source
AI summary
The present invention provides methods of treating patients infected with a coronavirus. In particular, provided are methods of treating or preventing COVID-19, or symptoms or complications thereof, in patients in need thereof using bardoxolone methyl or analogs thereof, and/or preventing the onset of COVID-19 in patients infected with SARS-COV-2.